Table 1.

Known oncogenic drivers with sensibility to targeted therapies in NSCLCs (7, 10–13).

Oncogenic drivers	Prevalence in NSCLCs (%)	EMA-approved tyrosine kinase inhibitors
EGFR mutations	11	Gefitinib, erlotinib, afatinib, osimertinib
ALK rearrangements	5	Crizotinib, ceritinib, alectinib, brigatinib, lorlatinib
MET exon 14 mutations	3–4	–
MET amplifications	2–4	–
BRAF V600E mutations	1–2	Dabrafenib + trametinib
RET rearrangements	1–2	–
NTRK rearrangements	0.1–1	–

EMA, European Medicine Agency; NSCLC, non small cell lung cancer.